1-20 of 78
Douglas Yee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO5-27-03: Mutational impact of APOBEC3A and APOBEC3B in a human cell line

Michael Carpenter, Nuri Temiz, Mahmoud Ibrahim, Matthew Jarvis, Margaret Brown, Prokopios Argyris, William Brown, Douglas Yee, Reuben Harris
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-27-03.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-27-03
Published: 02 May 2024
View article titled, Abstract PO5-27-03: Mutational impact of APOBEC3A and APOBEC3B in a human cell line
Journal Articles

Abstract 6804: High IL12family levels are associated with pathologic complete response amongst HER2- patients in the neoadjuvant I-SPY2 TRIAL

Kingsley V. Chow, Silver Al Khafaji, Denise Wolf, Christina Yau, Kailey Dubinsky, Elene Tsopurashvili, Kirthiga Ramalingam, Fluorentine van Nouhuijs, Zheyun Xun, Anna van Montfort, Diane Heditsian, Douglas Yee, Laura Esserman, Michael Campbell, Laura van't Veer, Rosalyn W. Sayaman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6804.
https://doi.org/10.1158/1538-7445.AM2024-6804
Published: 22 March 2024
View article titled, Abstract 6804: High IL12family levels are associated with pathologic complete response amongst HER2- patients in the neoadjuvant I-SPY2 TRIAL
Journal Articles

Abstract 1207: Immune subtyping identifies a subset of HR+HER2- early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL

Denise M. Wolf, Christina Yau, Lajos Pusztai, Rita Nanda, Jo Chien, Erica Stringer-Reasor, Rebecca Shatsky, Claudine Isaacs, MInetta Liu, Hyo Han, Hatem Soliman, Michael Campbell, Annuska Glas, Andrei Barcaru, Lorenza Mittempergher, Midas Kuilman, Lamorna Brown Swigart, Gillian Hirst, Hongmei Yu, Philip Beineke, Amrita Basu, I-SPY2 Investigators, Douglas Yee, W. Fraser Symmans, Angela DeMichele, Jane Perlmutter, Amy Delson, Laura Huppert, Hope Rugo, Amy Clark, Nola Hylton, Paula Pohlmann, Laura Esserman, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1207.
https://doi.org/10.1158/1538-7445.AM2024-1207
Published: 22 March 2024
View article titled, Abstract 1207: Immune subtyping identifies a subset of HR+HER2- early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL
Journal Articles

Abstract A014: Cell-free DNA concentration as a biomarker of response and recurrence in HER-2 negative breast cancer receiving neoadjuvant chemotherapy

Mark Jesus M. Magbanua, Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown-Swigart, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela M. DeMichele, Hope S. Rugo, Laura J. van ’t Veer
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): A014.
https://doi.org/10.1158/1538-7445.ADVBC23-A014
Published: 01 February 2024
View article titled, Abstract A014: Cell-free DNA concentration as a biomarker of response and recurrence in HER-2 negative breast cancer receiving neoadjuvant chemotherapy
Journal Articles

Abstract A003: Global and TNBC-specific biomarkers of sensitivity and resistance in early stage breast cancer from the I-SPY2 biomarker data compendium

Tam Binh V Bui, Denise M Wolf, Rosa I Gallagher, Julia Wulfkuhle, Christina Yau, Lamorna Brown-Swigart, Jennifer Rosenbluth, Douglas Yee, Gillian L Hirst, Laura J Esserman, Emanuel F Petricoin, Laura J Van 't Veer
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): A003.
https://doi.org/10.1158/1538-7445.ADVBC23-A003
Published: 01 February 2024
View article titled, Abstract A003: Global and TNBC-specific biomarkers of sensitivity and resistance in early stage breast cancer from the I-SPY2 biomarker data compendium
Journal Articles

Abstract A019: IGF-1R protein pathway activation is associated with pathologic complete response to an anti-IGF-1R regimen (paclitaxel, ganitumab, and metformin) in the I-SPY2 neoadjuvant breast cancer trial

Emanuel F. Petricoin, Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Laura van ‘t Veer, Rosa I. Gallagher, Gillian L. Hirst, Lamorna Brown-Swigart, Laura J. Esserman, Douglas Yee
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): A019.
https://doi.org/10.1158/1538-7445.ADVBC23-A019
Published: 01 February 2024
View article titled, Abstract A019: IGF-1R protein pathway activation is associated with pathologic complete response to an anti-IGF-1R regimen (paclitaxel, ganitumab, and metformin) in the I-SPY2 neoadjuvant breast cancer trial
Journal Articles

Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Erica Stringer-Reasor, Rebecca A. Shatsky, Jo Chien, Anne Wallace, Judy C. Boughey, Kathy S. Albain, Hyo S. Han, Rita Nanda, Claudine Isaacs, Kevin Kalinsky, Zahi Mitri, Amy S. Clark, Christos Vaklavas, Alexandra Thomas, Meghna S. Trivedi, Janice Lu, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van ’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD11-01.
https://doi.org/10.1158/1538-7445.SABCS22-PD11-01
Published: 01 March 2023
View article titled, Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Claudine Isaacs, Rita Nanda, Jo Chien, Meghna S. Trivedi, Erica Stringer-Reasor, Christos Vaklavas, Judy C. Boughey, Amy Sanford, Anne Wallace, Amy S. Clark, Alexandra Thomas, Kathy S. Albain, Laura C. Kennedy, Tara B. Sanft, Kevin Kalinsky, Hyo S. Han, Nicole Williams, Mili Arora, Anthony Elias, Carla Falkson, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): GS5-03.
https://doi.org/10.1158/1538-7445.SABCS22-GS5-03
Published: 01 March 2023
View article titled, Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents

Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Rosa I. Gallagher, Lamorna A. Brown Swigart, Gillian L. Hirst, Jean-Philippe Coppe, Mark Jesus M. Magbanua, Rosalyn Sayaman, I-SPY2 Investigators, Laura Sit, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Lajos Pusztai, Douglas Yee, Laura J. Esserman, Emanuel F. Petricoin, Laura Van ’t Veer
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD5-04.
https://doi.org/10.1158/1538-7445.SABCS22-PD5-04
Published: 01 March 2023
View article titled, Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents
Journal Articles

Abstract P2-26-13: Gene deletion of insulin receptor in MCF-7L breast cancer cells by CRISPR gene editing

Xihong Zhang, Marvis Monteiro, Douglas Yee
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-26-13.
https://doi.org/10.1158/1538-7445.SABCS22-P2-26-13
Published: 01 March 2023
View article titled, Abstract P2-26-13: Gene deletion of insulin receptor in MCF-7L breast cancer cells by CRISPR gene editing
Journal Articles

Abstract P2-03-02: Detection of insulin receptor isoforms by mass spectrometry in breast cancer

Xihong Zhang, LeeAnn Higgins, Todd Markowski, Tzu-Yi Yang, Jacob Wragge, Kevin Murray, Bruce Witthuhn, Albert Barrios, Douglas Yee
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-03-02.
https://doi.org/10.1158/1538-7445.SABCS21-P2-03-02
Published: 15 February 2022
View article titled, Abstract P2-03-02: Detection of insulin receptor isoforms by mass spectrometry in breast cancer
Journal Articles

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

David A Potter, Erin Roesch, Christina Yau, Ruixiao Lu, Denise Wolf, Susan Samson, Debra Stafford, Kathy S Albain, Claudine Isaacs, Meghana Trivedi, Douglas Yee, Judy Boughey, Alexandra Thomas, A. Jo Chien, Nola Hylton, Wen Li, Angela DeMichele, Jane Perlmutter, W. Fraser Symmans, Dawn L Hershman, Michelle Melisko, Laura J van 't Veer, Amy Wilson, Smita M Asare, Donald A Berry, Richard Schwab, Hope S Rugo, Laura J Esserman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD8-07.
https://doi.org/10.1158/1538-7445.SABCS21-PD8-07
Published: 15 February 2022
View article titled, Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Journal Articles

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-10-02.
https://doi.org/10.1158/1538-7445.SABCS21-OT1-10-02
Published: 15 February 2022
View article titled, Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer
Journal Articles

Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors

Sailaja Kamaraju, Amy Fowler, Chung Yee Cheng, Lubna N Chaudhary, John Burfeind, Janet Retseck, Amye J Tevaarwerk, Mark Burkard, Elisavet Paplomata, Amanda M Parkes, Julie M Jorns, Sergey Tarima, Douglas Yee, Hallgeir Rui, Carol Lange, Tarek Sahmoud, Kari B Wisinski
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-16-01.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-16-01
Published: 15 February 2022
View article titled, Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
Journal Articles

Abstract P4-02-01: Targeting insulin receptor in estrogen receptor positive breast cancer

Jingran Cao, Lynsey M. Fettig, Kelly LaPara, Xihong Zhang, Sylaja Murikipudi, Andrea R. Delpero, Thomas M. Lancaster, Todd C. Zion, Douglas Yee
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-02-01.
https://doi.org/10.1158/1538-7445.SABCS21-P4-02-01
Published: 15 February 2022
View article titled, Abstract P4-02-01: Targeting insulin receptor in estrogen receptor positive breast cancer
Journal Articles

Abstract P5-12-01: Apobec mutation signature in breast cancer explained by combinatorial action of apobec3a and apobec3b

Reuben S Harris, Matthew C Jarvis, Michael A Carpenter, Margaret R Brown, Prokopios P Argyris, William Brown, Douglas Yee
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-12-01.
https://doi.org/10.1158/1538-7445.SABCS21-P5-12-01
Published: 15 February 2022
View article titled, Abstract P5-12-01: Apobec mutation signature in breast cancer explained by combinatorial action of apobec3a and apobec3b
Journal Articles

Abstract PD9-02: Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P)

Mark Jesus M Magbanua, Denise Wolf, Derrick Renner, Svetlana Shchegrova, Lamorna Brown Swigart, Christina Yau, Gillian Hirst, Hsin-Ta Wu, Ekaterina Kalashnikova, Antony Tin, Amy Delson, Douglas Yee, Angela DeMichele, Raheleh Salari, Angel Rodriguez, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Paul Billings, Laura Esserman, Minetta Liu, Rita Nanda, Laura van ‘t Veer, I-SPY 2 Investigators
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD9-02.
https://doi.org/10.1158/1538-7445.SABCS20-PD9-02
Published: 15 February 2021
View article titled, Abstract PD9-02: Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P)
Journal Articles

Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer

Julia Wulfkuhle, Denise Wolf, Christina Yau, Lamorna Brown-Swigart, Rosa I Gallagher, Gillian Hirst, Laura Sit, Smita Asare, I-SPY 2 TRIAL Investigators, Nola Hylton, Angela DeMichele, Douglas Yee, Jo Chien, Hope Rugo, John Park, Kathy Albain, Rita Nanda, Debu Tripathy, Richard Schwab, Don Berry, Laura Esserman, Laura van t' Veer, Emanual Petricoin, III
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD9-04.
https://doi.org/10.1158/1538-7445.SABCS20-PD9-04
Published: 15 February 2021
View article titled, Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer
Journal Articles

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Heather Beckwith, Richard Schwab, Christina Yau, Erica Stringer-Reasor, Shi Wei, A. Jo Chien, Kathy S Albain, Kevin Kalinsky, Anne Wallace, Anthony Elias, Douglas Yee, Amy S Clark, Judy C Boughey, Heather Han, Rita Nanda, Claudine Isaacs, Zahi Mitri, Julie E Lang, Alexandra Thomas, Tara Sanft, Angela DeMichele, Jane Perlmutter, Hope S Rugo, Nola M Hylton, W. Fraser Symmans, Michelle E Melisko, Laura J van't Veer, I-SPY 2 Consortium, Amy Wilson, Smita M Asare, Ashish Sanil, Donald A Berry, Laura J Esserman
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD1-10.
https://doi.org/10.1158/1538-7445.SABCS20-PD1-10
Published: 15 February 2021
View article titled, Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Journal Articles

Abstract PS4-08: Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial

Douglas Yee, Paul Haluska, Denise M Wolf, Christina Yau, Amy Wilson, I-SPY2 TRIAL Consortium, Angela DeMichele, Claudine Isaacs, Jane Perlmutter, Joan Venticinque, Hope S Rugo, Richard Schwab, Nola M Hylton, W Fraser Symmans, Michelle E Melisko, Teresa L Helsten, Laura J van't Veer, Donald A Berry, Laura J Esserman
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS4-08.
https://doi.org/10.1158/1538-7445.SABCS20-PS4-08
Published: 15 February 2021
View article titled, Abstract PS4-08: Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial